Patient counseling about herbal-drug interactions

African Journal of Traditional, Complementary and Alternative Medicines

Volumn 8, Issue 5 SUPPL., 2011, Pages 152-163

  Hussain, Md Sarfaraj ^a  

^a INTEGRAL UNIVERSITY   (India)

Author keywords

Cytochrome P 450; Drug drug interaction; Herbal drug; Herbal Preparation; Herbal drug interaction

Indexed keywords

CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN; PLANT MEDICINAL PRODUCT;

CHEMISTRY; COUNSELING; HERB DRUG INTERACTION; HUMAN; MEDICINAL PLANT; METABOLISM; METHODOLOGY; PATIENT EDUCATION; REVIEW;

COUNSELING; CYTOCHROME P-450 ENZYME SYSTEM; HERB-DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEINS; PATIENT EDUCATION AS TOPIC; PLANT PREPARATIONS; PLANTS, MEDICINAL;

EID: 84872027503     PISSN: None     EISSN: 01896016     Source Type: Journal    
DOI: 10.4314/ajtcam.v8i5S.8     Document Type: Review

References (78)

1. Agrawal, O. P. and Raju, P.S. (2006). Traditional system of medicine. In: Abdin MZ and Abroi YP. (Eds.) Global Market of Herbal Products: Opportunities for India. Narosa Publishing House, New Delhi, India, 5-10.
2. Smith, M. (2000). Drug interactions with natural health products/dietary supplements: a survival guide. Paper presented at Complementary and Alternative Medicine: Implications for Clinical Practice and State-of-the-Science, Symposia, 2000 March 12, Boston, Mass.
3. Eisenberg, D. M., Davis, R. B. and Ettner, S. L. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 280, 1569-75.
4. Kaptchuk, T. J. and Eisenberg D. M. (1998). The persuasive appeal of alternative medicine. Ann. Intern. Med. 129, 1061-65.
5. Schultz, V., Hansel, R., and Tyler, V. E. (1998). Rational Phytotherapy: A Physician's Guide to Herbal Medicine. Berlin, Springer-Verlag.
6. Ernst, E. (2000). Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion. 13, 2200-2211.
7. Izzo A. A. (2004). Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int. J. Clin. Pharmacol. Ther. 42, 139-148.
8. Marechal, J. D., Kemp C. A., Roberts, G. C. K., Paine, M. J. I., Wolf, C. R. and Sutcliffe M. J. (2008). Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. B. J. Pharmacol. 153, S82-89.
9. Jacobs, B. P., Dennehy, C., Ramirez, G. J., Sapp and Lawrence, V. A. (2002). Milk thistle for the treatment of liver disease: a systematic review and metaanalysis. Amer. J. Med. 113, 506-515.
10. Rodriguez-Landa, J. F. and Contreras C. M. (2003). A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine. 10, 688-699.
11. Chavez, M. L., Jordan, M. A., Chavez, P. I. (2006). Evidence-based drug-herbal interactions. Life Sciences. 78. 2146-2157
12. Linde, K., Ramirez, G., Mulrow, C. D., Pauls, A., Weidenhammer, W. and Melchart D. (1996). St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BM. J. 313, 253-258.
13. Wheatley, D. (1997). LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial. Pharma. Psychiatry. 30, 77-80.
14. Hussain, M. S., Ansari, M. Z. H., Arif, M. (2009). Hyperforin: A lead for Antidepressants. Inter. J. Hea Res. 2(1), 15-22.
15. Nathan, P. (1999). The experimental and clinical pharmacology of St John's wort (Hypericum perforatum L.). Mol. Psychiatry. 4, 333-338.
16. Dewick, P. M. (1997). The biosynthesis of C5-C25 terpenoid compounds. National Productivity Report. 14, 111-144.
17. Wagner, H. (1986). Antihepatotoxic flavonoids. Prog in Clin. and Biol. Res. 213, 545-558.
18. Foster Steven and Tyler, V. E. (1999). Tyler's honest herbal: a sensible guide to the use of herbs and related remedies. Xxi, 1999, pp 442.
19. Schulz Volker., Hèansel Rudolf and Tyler, V. E. (2001). Rational phytotherapy: a physician's guide to herbal medicine. Xix, 383 pp.
20. rd ed, 35, 4540.
21. Meunier, B., De Visser S. P and Shaik S. (2004). Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 104, 3947-80.
22. Werck-Reichhart, D and Feyereisen R. (2000). Cytochromes P450: a success story. 1(6), Reviews 3003.
23. Degtyarenko, K. N. (1995). Structural domains of P450-containing monooxygenase systems. Protein Eng. 8 (8), 737-47.
24. Guengerich, F. P. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS. J. 8 (1), E101-11.
25. Guengerich, F. P. (1997). Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43, 7-35.
26. Munasinghe, T. M. (2002). Adverse drug reactions: monitoring, reporting and prevention. Ceylon. Med. J. 47(1), 19-21.
27. Glue, P and Clement, R. P. (1999). Cytochrome P450 enzymes and drug metabolism-basic concepts and methods of assessment. Mol. Neurobiol. 19 (3), 309-23.
28. Robertson, S. M., Penzak, S. R and Pau, A. K. (2005). Drug interactions in the management of HIV infection. Expert Opin. Pharmacother. 6, 233-53.
29. Warrington, J. S. and Shaw L. M. (2005). Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. Expert Opin. Drug Metab. Toxicol. 1, 487-503.
30. th ed. London: pharmaceutical Press.
31. Grenier, L. (2003). Less interactions medicamenteuses. In: L. Mallet, Grenier, L., Guimond, J., Barbeau, G., eds. Manuel de soins pharmaceutiques en gériatrie. Québec: Presses Del'Université de Laval. 131-52.
32. Nebert, D. W. and Russell D. W. (2002). Clinical importance of the cytochromes P450. Lancet. 360, 1155-62.
33. Christians, U. V. Schmitz and Haschke, M. (2005). Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert. Opin. Drug Metab. Toxicol. 1, 641-54.
34. Bista, D., Palaian, S., Shankar, P. R., Prabhu, M. M., Paudel, R. and Mishra, P. (2006). Understanding the essentials of drug interactions: A potential need for safe and effective use of drugs. Kath. Univ. Med. J. 4 (3), 421-430.
35. rd ed. Churchill Livingstone, Philadelphia. 21-31.
36. Lambrecht, J. E., Hamilton W. and Rabinovich A. (2000). A Review of Herb-Drug Interactions: Documented and Theoretical. US Pharmacist. 25 (8), 42-53.
37. Cupp, M. J. (1999). Herbal Remedies: adverse effects and drug interactions. Am. Fam. Physician. 59 (5), 1239-45.
38. Chan, T. Y. K. (1995). Adverse interactions between warfarin and nonsteroidal anti-inflammatory drugs: mechanisms, clinical significance, and avoidance. Ann. Pharmacother. 29, 1274-83.
39. Wijnands, W. J. A., Vree, T. B. and Baars, A. M. (1987). Steady state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin, and perfloxacin during maintenance treatment with theophylline. Drugs. 34 (1), 159-69.
40. Leon, A. S., Spiegel, H. E. and Thomas, G. (1971). Pyridoxine antagonism of levodopa in Parkinsonism. JAMA. 218, 1924-7.
41. Jusko, W. J. (1979). Influence of cigarette smoking on drug metabolism in man. Drug. Metab. Rev. 9, 221-36.
42. Kruth, P., Brosi, E., Fux, R., Morike, K. and Gleiter, C. H. (2004). Ginger associated over anticoagulation by phenprocoumon. Ann. Pharmacother. 38, 257-260.
43. Yue, Q. Y. and Jansson K. (2001). Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J. Am. Geriatr. Soc. 49(6), 838.
44. Izzat, M. B., Yim, A. P. and El-Zufari, M. H. (1998). A taste of Chinese medicine. Ann. Thorac. Surg. 66, 941-942.
45. Tam, L. S., Chan, T. Y., Leung, W. K., and Critchley, J. A. (1995). Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust. N Z. J. Med. 225-238.
46. Jiang, X., Williams, K. M., Liauw W. S. (2004). Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57, 592-599.
47. Meisel, C., Johne, A., Roots, I. (2003). Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 167(2): 367.
48. Legnani, C., Frascaro, M., Gauzzaloca, G. (1993). Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung; 43(2), 119-22.
49. Vuksan, V., Stavro, S. P., Sievenpiper, J. L. (2000). Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 23(9), 1221-26.
50. Hennessy, M., Kelleher, D., Spiers, J. P. (2002). St. John's Wort increases expression of Pglycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53(1), 75-82.
51. Cupp, M. J. (1999). Herbal Remedies: adverse effects and drug interactions. Am. Fam. Physician. 59(5), 1239-45.
52. Westendorf, J. Anthranoid derivatives-general discussion. In: DeSmet PAGM, et al, eds. (1993). Adverse Effects of Herbal Drugs. Berlin: Springer. 2, 105-118.
53. Mu, Y., Zhang, J., Zhang, S., Zhou, HH., Toma, D., Ren, S., Huang, L., Yaramus, M., Baum, A., Venkataramanan, R., Xie, W. (2006) Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J. Pharmacol. Exp. Ther. 316, 1369-1377.
54. Gaddis, G. M., Holt, T. R., Woods, M. (2002). Drug interactions in at-risk emergency department patients. Acad. Emerg. Med. 9, 1162-7. pply 1, Nov.-200
55. Schmider, J. and Brockmoller, J. (2002). Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J. Clin. Psychopharmacol. 22, 46-54.
56. Dannawi, M. (2002). Possible serotonin syndrome after combination of buspirone and St John's wort. J. Psychopharmacol. 16 (4), 401.
57. Gorski, J. C., Huang S. M. and Pinto A. (2004). The effect of Echinacea (Echinacea purpurea) root on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther. 89-100.
58. Mohammad, Y. M. I. (2009). Herb-drug interactions and patient counseling. Inter. J. Pharm & Pharm. Sci. 1, 151-161.
59. Chan, K., Lo, A. C., Yeung J. H. and Woo, K. S. (1995). The effects of danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J. Pharm. Pharmacol. 47(5), 402-406.
60. Tam, L. S., Chan, T. Y., Leung, W. K. and Critchley, J. A. (1995). Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust. N Z. J. Med. 25(3), 258.
61. Yu, C. M., Chan, J. C. and Sanderson J. E., (1997). Chinese herbs and warfarin potentiation by 'Danshen'. J. Intern. Med. 241(4), 337-339.
62. Lo, A. C., Chan, K., Yeung J. H. and Woo, K. S. (1995). Danggui (Angelica sinensis) affects the pharmacodynamics but not the pharmacokinetics of warfarin in rabbits. Eur. J. Drug. Met. Pharmacokinet. 20(1), 55-60.
63. Page, R. L. and Lawrence, J. D. (1999). Potentiation of warfarin by dong quai. Pharmacotherapy. 19(7), 870-876.
64. Granger, A. S. (2001). Ginkgo biloba precipitating epileptic seizures. Age Ageing. 30 (6), 523-525.
65. Bebbington, A., Kulkarni, R., Roberts, P. (2005). Ginkgo biloba: Persistent bleeding after total hip arthroplasty caused by herbal self-medication. J. Arthroplasty 20, 125-6.
66. Mohutsky, M. A, Anderson, G. D, Miller, J. W, Elmer, G. W. (2006). Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am. J. Ther. 13:24-31.
67. Boullata, J. (2005). Natural health product interaction with medication. Nutr. Clin. Pract. 20 (1), 33-51.
68. Hussain, S. H. (1999). Potential risks of health supplements-self-medication practices and the need for public health education. Int. J. Risk. Saf. Med. 12, 167-71.
69. Dietry Supplement-A Framework for Evaluating Safety, Institute of Medicine. National Academic Press 2005; Pp 235-246. http://www.nap.edu/book/0309091101/html(accessed August 31, 2005).
70. Izzo, A. A. (2005). Herb-drug interactions: an overview of the clinical evidence. Fund & Clin. Pharmacol. 19(1), 1-16.
71. Anon, 2002. Center for drug evaluation and research 2002. Report to the nation. Improving public health through human drugs. U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/reports/rtn/2002.Ptn2002.pdf.Accessed February 2, 2005.
72. Anon, 2001. Office of Inspector General, Department of Health and Human Services. Adverse event reporting for dietary supplements: an inadequate safety valve. April 2001, http://oig.hhs.gov/oei/reports/oei-01-00-00180. pdf. Accessed December 21, 2004.
73. Barnes, J., Mills, S. Y. and Abbott, N. C. (1998). Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face to face interviews with 515 users of herbal remedies. Br. J. Clin. Pharmacol. 45, 496-500.
74. Fugh-Berman, A. and Ernst, E. (2001). Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol. 52, 587-595.
75. Sorensen, J. M. (2002). Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J. Altern. Complement. Med. 8, 293-308.
76. Shannon, M. (1997). Drug-drug interactions and the cytochrome P450 system: an update. Pediatr. Emerg. Care. 13, 3502-3.
77. Barone, G. W., Gurley, B. J., Ketel B. L., Abul-Ezz, S. R. (2001). Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 71, 239-2 41.
78. Aga, V. M., Barklage, N.E., Jefferson, J. W. Linezolid. (2003). A monoamine oxidase inhibiting antibiotic, and antidepressants. J. Clin. Psychiatry. 64, 6092-11.